Phase III Trial of Ixabepilone plus Capecitabine Compared to Capecitabine Alone in Patients with Metastatic Breast Cancer (MBC) Previously Treated or Resistant to an Anthracycline and Resistant to Taxanes.

Reviewer: Eric Shinohara MD, MSCI
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 3 de junio del 2007

Translation for this article does not exist